2021 Year in Review - Multiple Myeloma
2021 Year in Review - Multiple Myeloma | February 23, 2022
The 18-month longer follow-up results of the ANDROMEDA study demonstrated sustained clinical benefits of D-VCd versus VCd in terms of hematologic and organ responses in patients with newly diagnosed light chain amyloidosis, with no additional safety signals.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Data from the ongoing phase 1/2 MajesTEC-1 study suggested that treatment with the BCMA x CD3 bispecific antibody teclistamab induced deep and durable responses in heavily pretreated patients with RRMM, with a manageable safety profile.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Updated results of the KarMMa trial showed that ide-cel CAR T-cell therapy resulted in durable and deep responses in heavily pretreated, triple-class–exposed patients with RRMM, supporting an overall favorable clinical benefit–risk profile.
2021 Year in Review - Multiple Myeloma | February 23, 2022
In 2022, the COVID-19 pandemic continues to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Updated results of the ICARIA-MM study demonstrated that addition of isatuximab to pomalidomide/low-dose dexamethasone led to significant improvements in efficacy outcomes compared with pomalidomide/low-dose dexamethasone alone in patients with RRMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Preliminary data suggest that patients with both MM and WM show impaired serologic responses following COVID-19 vaccines, with more severe impairment of COVID-19 S-protein antibody responses observed in the Waldenström macroglobulinemia cohort, and mRNA-1273 eliciting higher responses than other vaccines.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Results of a multicohort, phase 1/2 study indicated that the novel cereblon E3 ligase modulator iberdomide plus dexamethasone and daratumumab, bortezomib, or carfilzomib was associated with a tolerable safety profile and promising antitumor activity in patients with heavily pretreated RRMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Results of the CARDAMON trial indicate that, although carfilzomib maintenance was feasible and yielded higher MRD negativity rates at 6 months with ASCT than with consolidation, it was associated with a higher incidence of grade ≥3 adverse events and discontinuations after ASCT.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Interim analysis results of the phase 3 MAIA trial demonstrated that frontline daratumumab plus lenalidomide/dexamethasone provided OS benefit compared with lenalidomide/dexamethasone in patients with NDMM ineligible for stem-cell transplantation.
2021 Year in Review - Multiple Myeloma | February 23, 2022
In the CARTITUDE-2 cohort A that included patients with MM who had received 1 to 3 previous lines of therapy and were lenalidomide-refractory, a single infusion of cilta-cel CAR T-cell therapy produced early and deep responses, with a manageable safety profile.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512